Powder: -20°C for 3 years | In solvent: -80°C for 1 year
BMS-695735, a benzimidazole inhibitor of insulin-like growth factor-1 receptor, has broad-spectrum antitumor activity in vivo. It was found that BMS-695735 had strong inhibition of CYP3A4, induction of CYP3A4 mediated by PXR transactivation, poor water solubility, and high plasma protein binding.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
25 mg | 8-10 weeks | $ 1,970.00 | |
50 mg | 8-10 weeks | $ 2,580.00 | |
100 mg | 8-10 weeks | $ 3,400.00 |
Description | BMS-695735, a benzimidazole inhibitor of insulin-like growth factor-1 receptor, has broad-spectrum antitumor activity in vivo. It was found that BMS-695735 had strong inhibition of CYP3A4, induction of CYP3A4 mediated by PXR transactivation, poor water solubility, and high plasma protein binding. |
Synonyms | CHEMBL459729, DNC008930, BMS 695735, BMS695735, BDBM27888 |
Molecular Weight | 512.02 |
Formula | C26H31ClFN7O |
CAS No. | 1054315-48-8 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
BMS-695735 1054315-48-8 DNC-008930 CHEMBL459729 DNC 008930 DNC008930 CHEMBL-459729 BMS 695735 CHEMBL 459729 BMS695735 BDBM27888 BDBM-27888 BDBM 27888 inhibitor inhibit